Project Grant R43AG085856
Award Date
9/1/24
Completion Date
8/31/25
Dollars Obligated
$496K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Brooklyn, NY 11226, USA
Similar Awards
This $371,919 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) will support the development and validation of a high-throughput screening assay to identify drug candidates that can inhibit the misfolding and aggregation of tau protein, a key pathological driver of Alzheimer's disease. The goal is to adapt a tau protein misfolding cyclic amplification (tau-PMCA) assay into a robust, reproducible high-throughput screening (HT-TAU-PMCA) platform....
This $519,750 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a 2-year research study by the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco. The study aims to explore the underlying molecular mechanisms by which reducing levels of the tau protein can prevent or diminish excitation/inhibition imbalance and network hyperexcitability in the brain. This imbalance has been observed in various...
This $499,911 Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) is funding the development of a monoclonal antibody treatment for Alzheimer's disease (AD) targeting the acetylated tau protein. The awardee, Aeton Therapeutics Inc., has licensed murine monoclonal antibodies that bind to the AC-K174 tau epitope, which is highly expressed in the AD brain. Under this Phase I SBIR award, Aeton aims to: 1) evaluate the effectiveness of their...
This $431,750 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development and evaluation of a novel immuno-gene therapy approach for tauopathies, a group of neurodegenerative conditions including Alzheimer's disease. The key products and services to be delivered include: Generation and validation of a single-chain variable fragment (scFv) derived from a TAU oligomeric complex 1 (TOC1) antibody, coupled with a HaloTag protein and proteasome...
This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...
This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $1,012,534 to Eydis Bio, Inc. to develop orally bioavailable and blood-brain barrier penetrant, small molecule TAK1 inhibitors as a novel treatment for Alzheimer's disease. The grant, awarded on September 15, 2024, supports identifying and optimizing TAK1 inhibitors with the desired central nervous system-related pharmacological properties, which will be further evaluated in...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development of small-molecule degraders of the amyloid precursor protein (APP) as potential first-in-class drugs for Alzheimer's disease (AD) therapy. The total award amount is $499,883 and the award period runs from September 1, 2024 to August 31, 2025. The key products and services to be delivered under this grant include: Optimization of lead APP degrader compounds through...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $320,000 to the University of Texas Medical Branch at Galveston to conduct research on the role of tau protein and alternative polyadenylation (APA) in Alzheimer's disease. The study aims to comprehensively profile APA transcripts and gene expression in neurons expressing wild-type and mutant tau proteins, with the goal of better understanding how tau oligomerization impacts APA and...
The National Institute on Aging (NIA) awarded a $7,249,563 Project Grant under the Aging Research federal grant program (CFDA 93.866) to the Regents of the University of California, San Francisco (UCSF). This 3-year award, starting on Aug 1, 2023, will support research to characterize the structural properties and variability of tau protein aggregation in different brain cell types and at different disease stages of Alzheimer's and related dementias (ADRD). The project aims to develop new...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Baylor College of Medicine in the amount of $1,015,163 supports the development of a high-throughput in vivo CRISPR/Cas9 screening method to identify regulators of tau protein levels in the mouse brain. The primary objective is to bypass labor-intensive in vitro cell-based screens and directly screen for brain-specific regulators of tau, a protein implicated in Alzheimer's disease and other...